Amoxicillin healing phase — Competitive Intelligence Brief

Amoxicillin healing phase (Amoxicillin healing phase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic. Area: Infectious Disease.

phase 1 Beta-lactam antibiotic Penicillin-binding proteins Infectious Disease Small molecule

Target snapshot

Amoxicillin healing phase (Amoxicillin healing phase) — Belén Retamal-Valdes. Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amoxicillin healing phase TARGET	Amoxicillin healing phase	Belén Retamal-Valdes	phase 1	Beta-lactam antibiotic	Penicillin-binding proteins
CEPHALEXIN	CEPHALEXIN		marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)	1971-01-01
Rabeprazole, Amoxicillin	Rabeprazole, Amoxicillin	Mackay Memorial Hospital	marketed	Proton pump inhibitor + Beta-lactam antibiotic combination	H+/K+-ATPase (rabeprazole); Bacterial penicillin-binding proteins (amoxicillin)
Quick response: Amoxicillin for 3 days	Quick response: Amoxicillin for 3 days	University Hospital, Montpellier	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs)
Pseudomonas aeruginosa	Pseudomonas aeruginosa	Qilu Hospital of Shandong University	marketed	beta-lactam antibiotic	penicillin-binding proteins
Fosfomycin and imipenem	Fosfomycin and imipenem	Juan A. Arnaiz	marketed	Beta-lactam antibiotic combination	Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins)
β-lactams or ciprofloxacin	β-lactams or ciprofloxacin	University of Athens	marketed	Antibiotic (β-lactam and fluoroquinolone)	Penicillin-binding proteins (β-lactams); DNA gyrase and topoisomerase IV (ciprofloxacin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic class)

1. Pfizer · 2 drugs in this class
2. Bayer · 1 drug in this class
3. Belén Retamal-Valdes · 1 drug in this class
4. Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
5. Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
6. Incheon St.Mary's Hospital · 1 drug in this class
7. International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
8. KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
9. National Taiwan University Hospital · 1 drug in this class
10. Pfizer Inc. · 1 drug in this class